At my job recently, I've been researching certain pharmaceutical and biotechnology companies investments in emerging markets -- particularly Brazil, India and China -- and hot dog if these companies aren't licking their chops at the opportunities. Pricing pressures in the U.S. and Europe means that drug companies are going to increasingly rely on the exploding middle classes of BRIC countries to drive sales. Spending on drugs are going to double in emerging markets in the next five years, according to the New York Times - now that's a win/win for drug companies and B.Doyle. Oh yea, and for India.
 |
| Above: India and pharmaceutical companies, meeting for the first time. |
Needless, I'm going to walk to work with a little extra pep in my step tomorrow. Unless it's monsooning again...in that case I'll tell the rickshaw driver to sing that lil' Hindi diddy extra loud, for ol' B.Doyle. Fuck ya.
No comments:
Post a Comment